Room for improvement: tackling suboptimal downstream process unit operations for viral vectorsPublished: March 18, 2019
Dr Clive Glover, Prof. Daniel Smith, Dr Damian Marshall
VECTOR CHANNEL: PURIFICATION
Dr Clive Glover is Senior Global Marketing Manager, Cell & Gene Therapy, Pall Corporation, UK. Clive leads Pall’s cell and gene therapy business. Previously he was responsible for driving product development efforts around cell therapy at GE Healthcare and has also held positions in marketing and product management at STEMCELL Technologies. Clive holds a PhD in Genetics from the University of British Columbia.
Prof. Daniel Smith is Chief Scientific Officer at Cobra Biologics. Prior to his appointment as CSO in June 2014, Daniel was a Knowledge Transfer Manager and Senior Technologist for four years within the bioProcessUK team at the HealthTech & Medicines Knowledge Transfer Network.Formerly, Daniel spent five years at Cobra in roles including Senior Scientist, QC Team Leader, Head of Process Technology Transfer and Commercial Scientific Development Manager. He has over eight years academic research experience, 20+ research publications to his name and a PhD in Molecular Cell Biology. In June 2018 he was nominated an Honorary Industry Professor in the School of Life Sciences at the University of Warwick.
Dr Damian Marshall is the director of new and enabling technologies at the Cell and Gene Therapy Catapult and has almost 20 years of industrial experience gained working for SME’s and large companies. He is responsible for providing vision, expertise and leadership to a team of ~70 scientists working with a wide range of cell and gene therapy developers. Together they are addressing some of the barriers to growth within the industry, supporting the development of new technologies and helping create an advantageous environment that gives companies working in the UK a sustained competitive advantage.DOI: 10.18609/cgti.2019.024
Citation: Cell & Gene Therapy Insights 2019; 5(S2), 165-176.